Interventional, Open-label, One-sequence Crossover Study Evaluating the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics, Safety and Tolerability of Lu AF35700 in Healthy Young Men and Women
Phase of Trial: Phase I
Latest Information Update: 31 May 2017
At a glance
- Drugs LU AF-35700 (Primary) ; Itraconazole
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 23 May 2017 Planned End Date changed from 10 Oct 2017 to 10 Nov 2017.
- 23 May 2017 Planned primary completion date changed from 10 Oct 2017 to 10 Nov 2017.
- 07 Apr 2017 New trial record